Table 1.
Characteristics of the 16 tumor samples and the number of breakpoints and integration events detected in these samples.
| Patient-ID | HPV type | Stage | Breakpoints | Events | E6 | E7 | Follow-up (months) | Status at the end of follow-up |
|---|---|---|---|---|---|---|---|---|
| ZLR-01 | 16 | stage I | 2 | 1 | 2.9 | 8.1 | 49 | tumor-free |
| ZLR-02 | 16 | stage III | 2 | 1 | 140.8 | 460.2 | 30 | tumor-free |
| ZLR-03 | 16 | stage II | 3 | 1 | 67.5 | 177.5 | 28 | tumor-free |
| ZLR-04 | 16 | stage I | 3 | 1 | 91.4 | 212.8 | 63 | tumor-free |
| ZLR-05 | 16 | stage II | 0 | 0 | 52.3 | 146.4 | 51 | tumor-free |
| ZLR-06 | 16 | Stage II | 13 | 2 | 320.5 | 683.4 | 88 | tumor-free |
| ZLR-07 | 16 | Stage I | 2 | 0 | 115.1 | 236.4 | 90 | tumor-free |
| ZLR-08 | 16 | Stage I | 12 | 5 | 504.3 | 1213.7 | NA | NA |
| ZLR-09 | 16 | Stage II | 2 | 0 | 703.9 | 1261.5 | 61 | tumor-free |
| ZLR-10 | 16 | Stage I | 1 | 0 | 12.9 | 20.3 | 20 + 44 | relapse + tumor-free |
| ZLR-11 | 16 | Stage II | 10 | 4 | 600.1 | 1251.1 | 14 + 3 | relapse + deceased |
| ZLR-12 | 16 | Stage II | 4 | 3 | 271.6 | 539.2 | 54 + 18 | relapse + deceased |
| ZLR-13 | 16 | Stage II | 3 | 1 | 777.2 | 1719.0 | 90 | tumor-free |
| ZLR-14 | 16 | Stage II | 2 | 1 | 162.9 | 285.6 | 60 | tumor-free |
| ZLR-15 | 16 | Stage II | 2 | 1 | 152.1 | 218.0 | 62 | tumor-free |
| ZLR-16 | 16/58 | Stage II | 2 | 1 | 73.0 | 235.6 | 92 | tumor-free |
Histologic subtype of all 16 samples is squamous cell carcinoma (SCC); NA indicates data are not available. Expression levels of E6/E7 are quantified by transcript per million (TPM) in RNA-seq data.